医学
血糖性
连续血糖监测
2型糖尿病
糖尿病
胰岛素
1型糖尿病
随机对照试验
目标射程
血糖自我监测
自我监控
临床试验
研究设计
食物摄入量
内科学
2型糖尿病
基线(sea)
物理疗法
年轻人
作者
Holly J Willis,Sally K. Gustafson,Elizabeth M. Johnson,Meghan M. JaKa,Richard M. Bergenstal
标识
DOI:10.1177/15209156251377799
摘要
Introduction: Preliminary research suggests that continuous glucose monitoring (CGM) can be used to guide food and lifestyle choices. The objective of the Using Nutrition to Improve Time in rangE (UNITE) study was to compare the glycemic and dietary impact of using either a nutrition-focused approach (NFA) or a self-directed approach (SDA) during CGM initiation in people with type 2 diabetes (T2D) not on insulin. Methods: UNITE was a 60-day, two-arm, randomized clinical trial. The NFA arm was designed to help participants use CGM data to guide evidenced-based food choices to improve percent time in range with glucose 70–180 mg/dL (TIR70-180) and diet quality, whereas the SDA arm was designed to guide participants to use CGM data in any way that felt useful to them. Changes in outcomes from baseline (Base) to postintervention (Post) were estimated by arm and compared between arms using difference-in-differences; analyses were limited to those with adequate CGM data at Base and Post. Results: Adults (NFA: N = 64, SDA: N = 60) with a mean (standard deviation) age of 65.0 (10.3) years, T2D duration of 10.7 (6.5) years, and HbA1c of 7.9% (0.7) participated. There was no differential change in TIR70-180 between arms ( P = 0.14), but both arms improved from Base to Post (NFA: 46%–71%, SDA: 55%–71%; within-arm differences both P < 0.001). Time with glucose >250 mg/dL decreased more from Base to Post in the NFA versus the SDA (−14% versus −6%; differential change P = 0.047). NFA participants had several minor, but significant, within-arm changes in dietary intake, and the NFA arm reported significantly more confidence using CGM data than the SDA arm ( P < 0.05). Conclusion: Changes in mean TIR70-180 did not differ between the NFA and SDA arms; however, both arms experienced significant within-arm improvements, which support the use of CGM to improve glycemia in people with T2D not on insulin.
科研通智能强力驱动
Strongly Powered by AbleSci AI